Mandate

Vinge advises Cell Impact AB (publ) in connection with a directed share issue

Vinge has advised Cell Impact AB (publ) in connection with a directed share issue, whereby Cell Impact receives proceeds of SEK 175 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. The purpose of the share issue is to finance Cell Impact’s continued path towards commercialization and expand the production capacity in the new factory in order to pave the way for expanded serial production.

Vinge’s team has consisted of Johan Larsson, Dain Hård Nevonen, Rikard Lindahl, Maria Dahlin-Kolvik, Joel Magnusson, Vilhelm Rondahl and Linnea Petersson.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025